On March 30, 2026, PharmaCyte Biotech, Inc. held its annual meeting, where stockholders approved an increase of 2 million shares for the company's 2022 Equity Incentive Plan. The meeting saw 55.08% of shares represented, with various proposals voted on, including a reverse stock split.